By accurately defining the drug exposure levels that affect QRS duration, researchers can establish safety margins, prioritise lower-risk compounds, and reduce the chance of late-stage failures due to cardiac toxicity
Enhance predictive accuracy, reduce false negatives and late-stage failures for safer drug development with improved preclinical-to-clinical translationRecordings using voltage-sensitive dye (VSD) with quality equivalent to patch-clamp are crucial for assessing cardiovascular risk in drug discovery. They provide a high-fidelity, high-throughput alternative to traditional electrophysiology techniques.
VSD-based recordings offer non-invasive, high-resolution measurements of membrane potential changes across a large number of cells or wells simultaneously, enabling faster and more efficient cardiac safety screening. This approach ensures precise detection of drug-induced effects on cardiac ion channels, such as hERG (IKr), Nav1.5, and Cav1.2, which are critical for evaluating proarrhythmic risk.
The ability to achieve patch-clamp-equivalent data quality using VSD enhances predictive accuracy, reducing false negatives and late-stage failures, and supports safer drug development with improved preclinical-to-clinical translation.
Read more about our hiPSC cardiomyocyte assay.
By accurately defining the drug exposure levels that affect QRS duration, researchers can establish safety margins, prioritise lower-risk compounds, and reduce the chance of late-stage failures due to cardiac toxicity
We demonstrate the generation and validation of a stable CHO-hHCN2 cell line used as a cellular tool in the successful development of hHCN2 automated electrophysiology screening assays.